Solvonis Therapeutics (LSE:SVNS) Buildings And Improvements : £0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Buildings And Improvements?

Solvonis Therapeutics's annual buildings and improvements increased from May. 2021 (£0.00 Mil) to Dec. 2022 (£0.09 Mil) but then declined from Dec. 2022 (£0.09 Mil) to Dec. 2023 (£0.00 Mil).

Solvonis Therapeutics Buildings And Improvements Historical Data

The historical data trend for Solvonis Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Buildings And Improvements Chart

Solvonis Therapeutics Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

0.03

0.09

Solvonis Therapeutics Quarterly Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Buildings And Improvements	Get a 7-Day Free Trial								-	-	-	-	-

Solvonis Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines